The patient was a 66-year-old man with end-stage kidney disease from diabetes. Blood group O. More than five years on the transplant waiting list. No living donor. In January 2025, instead of another dialysis session, he received a kidney from a pig.

A pig with 69 genomic modifications, but still a pig.

Nine months later, that kidney came out. Six weeks after that, he received a human kidney. As of September 2026, his creatinine is running between 1.0 and 1.1 mg/dL. He is doing well. His xenograft kept him off dialysis for 82 days while he waited for the human allograft. Those were the 82 days the pig kidney was for.

This is the story of that case. It was published in The Lancet by Riella and colleagues in 2026. It is a case report. N equals 1. The authors say this themselves. Draw conclusions accordingly.

The xenograft came from eGenesis, a company that also funded the study, designed the protocol, provided the pig, and has multiple authors on the paper as employees or equity holders. The kidney, designated EGEN-2784, was engineered with three pig carbohydrate antigen genes knocked out (GGTA1, CMAH, B4GALNT2), seven human transgenes inserted for immune modulation, and all porcine endogenous retroviruses (PERVs) inactivated through CRISPR.

The immunosuppression protocol was aggressive: tegoprubart (anti-CD154, supplied by Eledon Pharmaceuticals), belatacept, mycophenolate mofetil, steroids, and pegcetacoplan (a complement C3 inhibitor supplied by Apellis Pharmaceuticals). Both drug companies also appear in the conflicts-of-interest section.

The graft worked immediately. A biopsy at day 14 showed T-cell mediated rejection at Banff grade IIA. Treatment resolved it. Things looked good enough that pegcetacoplan was stopped around day 90.

Around day 170, thrombotic microangiopathy appeared. The graft deteriorated. There was also a MRSA bacteremia at day 226 that required immunosuppression reduction. By day 271, the decision was made to explant.

Critically: no PERV transmission was detected. No sensitization to human HLA antigens occurred after explant. The subsequent human allograft is functioning well.

This is the scientifically interesting part of the paper. Not that the xenograft worked, but how it failed. Conventional xenograft rejection follows an antibody cascade. This did not. If the innate immune pathway hypothesis is correct, it implies that complement inhibition may need to be continuous rather than perioperative only.

Pegcetacoplan was stopped around day 90. The TMA appeared around day 170. The authors acknowledge this sequence. They do not claim causality. They do note it as a potential confounder. It is a significant one.

What this means practically: the complement story in xenotransplantation is not closed. It may need to be reopened at a mechanistic level, with the innate immune axis as the primary target rather than humoral immunity.

Let's be specific. eGenesis funded this study. eGenesis provided the pig kidney. eGenesis contributed to study protocol design. Four authors (S.C.L., M.C., K.G., S.P.) are eGenesis employees. Multiple additional authors report consulting fees, investigator-initiated grants, stock options, or equity in eGenesis. The paper also lists financial relationships with Eledon Pharmaceuticals (tegoprubart) and Apellis Pharmaceuticals (pegcetacoplan), both of which supplied drugs used in the protocol.

The authors state that eGenesis had no role in data analysis, interpretation of results, or writing of the manuscript. That is a meaningful declaration and standard practice for industry-sponsored investigator-initiated trials. The disclosure section is complete and detailed.

This does not mean the findings are wrong. It means the findings require independent replication before they can anchor clinical policy. The structural tension between "the company that makes the product" and "the study that evaluates it" does not resolve through disclosure alone. Disclosure is necessary. It is not sufficient.

One additional note: the patient selection criteria were extensive. Age 50 to 70, no available living donor, extended waiting time, specific comorbidity profile, multidisciplinary evaluation, implantable loop recorder placed preoperatively. This is a highly curated patient. Generalizing to the broader ESKD population is not yet supported.

Here is where the authors deserve credit. The abstract does not oversell. The discussion section explicitly states: "The absence of a comparison group, the complexity of the clinical factors encountered, and our reliance on histological characterization to infer pathophysiological mechanisms restrict definitive conclusions."

That sentence is doing honest work. When the methods section of a paper warns you not to over-interpret the results, take the warning. The authors are not claiming that xenotransplantation is ready for widespread use. They are reporting a single case that has features worth understanding. That framing is appropriate.

The news coverage of this paper will not be that measured. It rarely is.